Menu Close

Trending

Sanofi pauses enrolment in ex-US tolebrutinib trials
The challenges and opportunities for kidney cancer care recovery
The Rise of Influencer Marketing: How Patient Leaders Bring Value to Campaigns
Koneksa aims to answer Parkinson’s-tracking challenge with AI
Verona cues up filings for COPD drug after it aces phase 3 test

AskBio

Close Up Of Senior Man Suffering With Parkinsons Diesease

News/ News/ R&D

Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinic

, , , , , , 0 Comment

Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson’s disease patient in a phase 1 trial of its

X
Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinic
https://pharmaphorum.com/news/bayers-two-pronged-cell-gene-therapy-assault-on-parkinsons-enters-clinic/

Login

CONTINUE TO SITE >
X
Close in 10 seconds